financial results

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The firm attributed growth to a diversified geographic footprint and comprehensive offerings based on three key in vitro diagnostics technologies.

The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.

The company, which merged with Transgenomic in 2016, attributed the revenue increase to strong demand for its pathology services.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

The company had £13.8 million ($18.4 million) in revenues and a net loss of £56.6 million in 2017.

The firm said that the decline was due to a customer shifting to internalizing genetic ordering, adverse weather, and the loss of an undisclosed commercial payor.  

Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.

The revenue increase was driven in part by surging direct sales of the firm's diagnostic test cartridges and instruments in Europe, the Middle East, and Asia.

The company had to halt and later restart billing for its cancer risk assessment tests as it transitioned to a new billing process.